GMAB vs SRPT

For growth investors, Genmab A/S (GMAB) is the stronger pick with 30.

7% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Genmab A/S (GMAB) offers the better valuation at 14. 6x trailing P/E (24. 0x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sarepta Therapeutics, Inc.

is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Genmab A/S (GMAB) delivered a total return of -25.

1%, compared to -69. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: GMAB returned +90. 4% versus SRPT's +30. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Genmab A/S (GMAB) is the lower-risk stock at 0.

94β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 116% more volatile than GMAB relative to the S&P 500. On balance sheet safety, Genmab A/S (GMAB) carries a lower debt/equity ratio of 3% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Genmab A/S (GMAB) is pulling ahead at 30.

7% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Genmab A/S grew EPS 83. 9% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, GMAB leads at 36. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 36.

4% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31. 1% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — GMAB leads at 95. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 7. 7x forward P/E versus 24. 0x for Genmab A/S — 16. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 43. 1% to $39. 90.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Genmab A/S (GMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94)). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GMAB: +90. 4%, SRPT: +30. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.